PHAR 200 Midterm: Gout: Febuxostat
Document Summary
Febuxostat is fda approved for chronic hyperuricemia associated with gout. Because of its potency and rapid reduction of sua levels, prophylactic low-dose colchicine or an. Nsaid is recommended for 3 to 6 months during initiation of therapy. Febuxostat is more effective than allopurinol in achieving target sua levels and may be more effective in reducing the number of acute gouty flares. Because of cost concerns, febuxostat should be reserved for patients who do not tolerate allopurinol or those who cannot achieve target sua levels despite allopurinol therapy. Febuxostat is a non-purine xanthine oxidase inhibitor structurally distinct from allopurinol. Febuxostate is highly metabolized into inactive metabolite by the liver. Probenecid is indicated in gouty patients when allopurinol or febuxostat is contraindicated or when tophi are present. Contraindicated with a history of uric acid stones or nephropathy. Should not be used if creatinine clearance (crcl) is < 50 ml/min.
